Claims for Patent: 11,117,867
✉ Email this page to a colleague
Summary for Patent: 11,117,867
Title: | Crystalline salts of a plasma kallikrein inhibitor |
Abstract: | Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention. ##STR00001## |
Inventor(s): | El-Kattan; Yahya (Vestavia Hills, AL), Babu; Yarlagadda S. (Birmingham, AL) |
Assignee: | BioCryst Pharmaceuticals, Inc. (Durham, NC) |
Application Number: | 16/784,016 |
Patent Claims: |
1. A pharmaceutical composition, comprising a crystalline salt of Compound I, ##STR00009## and a pharmaceutically acceptable carrier; wherein the pharmaceutical composition is an
oral dosage form; and the oral dosage form contains about 75 mg to about 250 mg of the crystalline salt of Compound I.
2. The pharmaceutical composition of claim 1, wherein the crystalline salt of Compound I is a hydrochloride salt. 3. The pharmaceutical composition of claim 1, wherein the crystalline salt of Compound I is a bis(hydrochloride) salt. 4. The pharmaceutical composition of claim 3, wherein the oral dosage form contains about 75 mg to about 175 mg of the crystalline salt of Compound I. 5. The pharmaceutical composition of claim 3, wherein the oral dosage form contains about 100 mg to about 250 mg of the crystalline salt of Compound I. 6. The pharmaceutical composition of claim 3, wherein the oral dosage form contains about 100 mg to about 200 mg of the crystalline salt of Compound I. 7. The pharmaceutical composition of claim 3, wherein the oral dosage form contains about 100 mg to about 175 mg of the crystalline salt of Compound I. 8. The pharmaceutical composition of claim 3, wherein the oral dosage form contains about 125 mg to about 250 mg of the crystalline salt of Compound I. 9. The pharmaceutical composition of claim 3, wherein the oral dosage form contains about 125 mg to about 200 mg of the crystalline salt of Compound I. 10. The pharmaceutical composition of claim 3, wherein the oral dosage form contains about 125 mg to about 175 mg of the crystalline salt of Compound I. 11. The pharmaceutical composition of claim 3, wherein the oral dosage form contains about 150 mg of the crystalline salt of Compound I. 12. The pharmaceutical composition of claim 3, wherein the oral dosage form is a capsule, an ingestible tablet, a buccal tablet, a troche, an elixir, a suspension, a syrup, a powder, or a wafer. 13. The pharmaceutical composition of claim 3, wherein the oral dosage form is a capsule. 14. A method of treating a disease or condition characterized by aberrant plasma kallikrein activity, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1. 15. The method of claim 14, wherein the disease or condition characterized by aberrant plasma kallikrein activity is selected from the group consisting of stroke, inflammation, reperfusion injury, acute myocardial infarction, deep vein thrombosis, post fibrinolytic treatment condition, angina, edema, angioedema, hereditary angioedema, sepsis, arthritis, hemorrhage, blood loss during cardiopulmonary bypass, inflammatory bowel disease, diabetes mellitus, retinopathy, diabetic retinopathy, diabetic macular edema, diabetic macular degeneration, age-related macular edema, age-related macular degeneration, proliferative retinopathy, neuropathy, hypertension, brain edema, increased albumin excretion, macroalbuminuria, and nephropathy. 16. The method of claim 15, wherein the disease or condition characterized by aberrant plasma kallikrein activity is angioedema. 17. The method of claim 15, wherein the disease or condition characterized by aberrant plasma kallikrein activity is hereditary angioedema. 18. A method of preventing or treating angioedema attacks in a subject with hereditary angioedema, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1. 19. A method of reducing the frequency of angioedema attacks in a subject with hereditary angioedema, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1. 20. A method of treating an acute angioedema attack in a subject with hereditary angioedema, comprising administering to a subject in need thereof the pharmaceutical composition of claim 1. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.